How do you approach duration of immunotherapy in patients with metastatic NSCLC?

Does your approach depend on the patient’s response or PD-L1 level? Are there any studies supporting immunotherapy’s use beyond 2 years?

Answer from: Medical Oncologist at Community Practice

If someone manages to continue the ICI maintenance up to 2 years without progression, I am comfortable counseling the patient to stop the ICI treatment as per the regulatory approval indication. I have had occasionally, patient's anxiety level driving the desire to continue beyond the 2 years treatm...

Answer from: Medical Oncologist at Academic Institution

In patients with metastatic NSCLC on immunotherapy without progression at 2 years, I discuss with patients the option of stopping immunotherapy vs continuing it, and then we make a mutual decision in this regard. This is guided by this retrospective review from 2023.Sun et al., PMID 37270700

Comments

Medical Oncologist at Onc San Antonio
How do you navigate continuation beyond 2 years, i...

Please select the option that best describes you:

How do you approach duration of immunotherapy in patients with metastatic NSCLC?

Related Questions